TAS1R2 c.718C>G ;(p.L240V)

Variant ID: 1-19181246-G-C

NM_152232.2(TAS1R2):c.718C>G;(p.L240V)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.

Journal For Immunotherapy Of Cancer
Reuss, Joshua E JE; Anagnostou, Valsamo V; Cottrell, Tricia R TR; Smith, Kellie N KN; Verde, Franco F; Zahurak, Marianna M; Lanis, Mara M; Murray, Joseph C JC; Chan, Hok Yee HY; McCarthy, Caroline C; Wang, Daphne D; White, James R JR; Yang, Stephen S; Battafarano, Richard R; Broderick, Stephen S; Bush, Errol E; Brock, Malcolm M; Ha, Jinny J; Jones, David D; Merghoub, Taha T; Taube, Janis J; Velculescu, Victor E VE; Rosner, Gary G; Illei, Peter P; Pardoll, Drew M DM; Topalian, Suzanne S; Naidoo, Jarushka J; Levy, Ben B; Hellmann, Matthew M; Brahmer, Julie R JR; Chaft, Jamie E JE; Forde, Patrick M PM
Publication Date: 2020-09

Variant appearance in text: TAS1R2: L240V
PubMed Link: 32929052
Variant Present in the following documents:
  • jitc-2020-001282supp004.xlsx, sheet 2
View BVdb publication page